NCT06532032View on ClinicalTrials.gov

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

October 21, 2025

Study Completion Date

June 9, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Amivantamab

Amivantamab will be administered as IV infusion.

DRUG

Docetaxel

Docetaxel will be administered as IV infusion.

Trial Locations (15)

110

Taipei Medical University, Taipei

500

Changhua Christian Hospital, Changhua

736

Chi Mei Medical Center Liu Ying, Liou Ying Township

10043

National Taiwan University Hospital, Taipei

22031

Virginia Cancer Specialists, Fairfax

40705

Taichung Veterans General Hospital, Taichung

65807

Oncology Hematology Associates, Springfield

80708

Kaohsiung Medical University Hospital, Kaohsiung City

90720

Cancer and Blood Specialty Clinic, Los Alamitos

92612

UCI Health Irvine Hospital, Irvine

92868

University of California Irvine Medical Center Chao Family Comprehensive Cancer Center, Orange

08822

Hunterdon Hematology Oncology, Flemington

06800

Ankara Bilkent Sehir Hastanesi, Çankaya

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

SM2 5PT

The Royal Marsden NHS Trust, Sutton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT06532032 - A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter